Quote:

---

Ipilimumab Safety Profile:
Associated with a higher risk of immune-related adverse events (irAEs) compared to other immune checkpoint inhibitors.
Common side effects include:
Diarrhea
Rash
Fatigue
Nausea and vomiting
Abdominal pain
Anorexia/weight loss
More severe irAEs can include:
Enterocolitis (inflammation of the intestines)
Hepatitis (inflammation of the liver)
Dermatitis (skin inflammation)
Neuropathy (nerve damage)
Endocrinopathy (hormone problems)
These irAEs can be severe or even fatal.

---

No surprise there. Many drugs cause problems with a complete blockade of a specific vital pathway. In the case of Ipilimumab it blocks CLTA-4. Cancer uses CLTA-4 on immune cells to evade detection by killer T-cells. But the main role of CTLA-4 is to protect normal cells from autoimmunity caused destruction. Leronlimab only downregulates CLTA-4. Not quite as effective as Ipilimumab but also not causing those rtpes of side effects.